ArticleCNS drugs2026
Parental Cardiometabolic History, Family Income, and Cardiometabolic Risk in Antipsychotic-Treated Children, Adolescents, and Young Adults: A Nationwide Cohort Study.
Article in CNS drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildren and adolescents treated with antipsychotics are at increased risk of cardiometabolic adverse events (CMAEs). It is unclear how far this risk is shaped by parental CMAE history or socioeconomic status.
objectivesWe examined whether parental CMAE history and family income modify the cardiometabolic risk associated with antipsychotic use in children, adolescents, and young adults.
methodsWe conducted a nationwide cohort study of Danish children and adolescents (aged 6-17 years) and young adults (aged 18-31 years) with psychiatric diagnoses treated with antipsychotics in 2000-2021. Each exposed individual was age/sex-matched to up to 10 controls. The outcome was any CMAE, identified through hospital contacts or related prescriptions. Using propensity score weighting, we estimated weighted incidence rates (wIR) and incidence rate ratios (wIRR) with 95% confidence intervals (CIs), stratified by parental CMAE history and family income.
resultsThe cohort comprised 8488 children/adolescents and 27,326 young adults treated with antipsychotics, and 293,678 unexposed controls. Among children/adolescents, CMAE incidence increased with the number of parents with CMAE (wIR
conclusionsAbsolute CMAE risk rose with each affected parent, whereas the antipsychotic-related relative risk was largest in offspring with no affected parent. Higher family income was associated with lower risk in both age groups. Both family history of CMAEs and socioeconomic context should inform antipsychotic prescribing as well as cardiometabolic monitoring and preventive strategies, particularly in children and adolescents.
Identifiers
42859316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.